Eutilex Co.,Ltd.
Develops immunotherapeutics for cancers and autoimmune diseases via T-cell/antibody tech.
263050 | KO
Overview
Corporate Details
- ISIN(s):
- KR7263050007
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 금천구 가산디지털1로 58 408호 (가산동, 에이스한솔타워), 서울특별시
- Website:
- https://www.eutilex.com/en/
- Sector:
- Manufacturing
Description
Eutilex Co., Ltd. is a biotechnology company focused on the research and development of immunotherapeutics for cancers and autoimmune diseases. The company's core approach involves selecting targets that enhance or suppress human immune responses. Its pipeline is centered on three primary technology platforms: T-cell therapy, antibody therapy, and CAR-T cell therapy. Key development programs include adoptive T-cell therapies, such as those based on 4-1BB cytotoxic T lymphocytes (CTL), and various immunomodulatory antibody therapeutics designed to treat a range of incurable diseases.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-03-12 00:00 |
주주총회소집공고
|
Korean | 178.6 KB | ||
| 2020-03-06 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 23.5 KB | ||
| 2020-02-28 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 23.6 KB | ||
| 2020-02-21 00:00 |
투자판단관련주요경영사항(앱비앤티셀 국내 1/2상 식품의약품 안전처로 부터 임상시험 재개 통보)
|
Korean | 9.8 KB | ||
| 2020-02-21 00:00 |
기타경영사항(특허권취득)(자율공시)(IFN- -유도성 조절 T 세포 전환가능 항암 (IRTCA) 항체 및 그의 용도 미국 특허 취득)
|
Korean | 5.3 KB | ||
| 2020-02-14 00:00 |
매출액또는손익구조30%(대규모법인은15%)이상변동
|
Korean | 12.8 KB | ||
| 2020-01-17 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 23.6 KB | ||
| 2020-01-17 00:00 |
주식등의대량보유상황보고서(일반)
|
Korean | 108.6 KB | ||
| 2020-01-10 00:00 |
임원ㆍ주요주주특정증권등소유상황보고서
|
Korean | 23.6 KB | ||
| 2020-01-03 00:00 |
주식매수선택권행사
|
Korean | 16.5 KB | ||
| 2019-12-16 00:00 |
주주명부폐쇄기간또는기준일설정
|
Korean | 4.3 KB | ||
| 2019-12-05 00:00 |
기타경영사항(특허권취득)(자율공시)
|
Korean | 5.5 KB | ||
| 2019-11-14 00:00 |
분기보고서 (2019.09)
|
Korean | 982.6 KB | ||
| 2019-10-29 00:00 |
기타경영사항(특허권취득)(자율공시)(항 인간 4-1BB 항체와 그 용도 (Anti-human 4-1BB antibodies and uses t…
|
Korean | 5.0 KB | ||
| 2019-10-17 00:00 |
기타경영사항(특허권취득)(자율공시)(HAR-NDS 유래 줄기세포, 그 분리방법 및 용도 중국특허 취득)
|
Korean | 5.2 KB |
Automate Your Workflow. Get a real-time feed of all Eutilex Co.,Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Eutilex Co.,Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Eutilex Co.,Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
